A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

NCT06600321 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

158

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma
Metastatic Hepatocellular Carcinoma

Interventions

DRUG: ALN-BCAT
DRUG: Pembrolizumab

Sponsor

Alnylam Pharmaceuticals